ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
- Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development
Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors.
Dr. Pamela Klein is a medical oncologist and seasoned biotechnology executive with 20 years of experience in drug development. Amongst multiple roles and experience, she is a member of the Board of Directors of Argenx, Patrys and I-Mab Biopharma as well as a member of several Scientific Advisory Boards. Dr. Klein was previously Chief Medical Officer of Olema Oncology and previously served in that role for multiple successful biotech companies including Intellikine which was acquired by Takeda. From 2001-2008, Dr. Klein held increasing positions of responsibility at Genentech lastly as Vice President, Development, where she led the development for a portfolio of drugs including Herceptin®, Rituxan®, Perjeta®, and Tarceva®. Prior to this, Dr. Klein was Research Director for the National Cancer Institute-Navy Breast Care Center that she co-founded and led until leaving the NCI.
Dr. Klein received her bachelor’s degree in biology from California State University and her Medical Degree from Stritch School of Medicine, Loyola University Chicago. She trained in internal medicine at Cedars-Sinai Medical Center in Los Angeles and medical oncology at the National Cancer Institute in Bethesda, Maryland where she served as Chief Fellow.
Valerie Vanhooren, Ph.D., Co-founder & Chief Executive Officer of ONA Therapeutics, said: “I am delighted to welcome Pamela to the board at a pivotal time of Company growth with her proven track record in developing therapies that have raised the bar in patient care. Pamela’s insight and unparalleled experience in the field of oncology will be invaluable as we advance our treatments for advanced cancer towards clinical development.”
Dr Pamela Klein, Member of the Board of Directors at ONA Therapeutics, commented: “I look forward to working with the team at ONA Therapeutics, whose novel approach has the potential to make a real difference and improve patient outcomes with advanced cancer.”
ONA Therapeutics is developing novel therapies against advanced cancer and will be profiled in Nature on the 25 of May as a thriving, preclinical, mature Company which is accelerating development of its novel pipeline towards clinical development.
